$14.18
-0.44[-3.01%]
At close: Apr 25
$14.18
0[0.00%]
After Hours: 4:20PM EDT
Deciphera Pharmaceuticals
(NASDAQ:DCPH)Latest News for Deciphera Pharmaceuticals Stock (NASDAQ:DCPH)
Deciphera Pharmaceuticals Stock (NASDAQ: DCPH)
Categories: All
Tuesday, February 06, 2024
- Deciphera Pharmaceuticals' Cash Position As of December 31, 2023 Were $352.9M, Which Is expected To Provide Cash Runway Into Second Half Of 2026Benzinga Newsdesk - Feb 6, 2024, 7:03AM
- Deciphera Pharmaceuticals Q4 EPS $(0.54) Beats $(0.58) Estimate, Sales $48.30M Beat $45.92M EstimateBenzinga Newsdesk - Feb 6, 2024, 7:01AM
- Earnings Scheduled For February 6, 2024Benzinga Insights - Feb 6, 2024, 5:42AM
Monday, February 05, 2024
Thursday, January 18, 2024
- Deciphera Pharmaceuticals Results Of INTRIGUE Study Long-Term Follow-Up, In The Primary Analysis Of The AP-ITT Population Based On A Data Cut Of September 1, 2021, The Primary Endpoint Was Not achievedBenzinga Newsdesk - Jan 18, 2024, 11:17AM
- Deciphera Pharmaceuticals Presents Long-Term Follow-Up Results From INTRIGUE Phase 3 Clinical Study In Second-Line GIST Patients At The 2024 American Society Of Clinical Oncology Gastrointestinal Cancers SymposiumBenzinga Newsdesk - Jan 18, 2024, 11:14AM
Monday, January 08, 2024
- Deciphera Pharmaceuticals Preliminary Unaudited Cash, Cash Equivalents, and Marketable Securities Of Approximately $352M As Of December 31, 2023; Cash Runway Extended into the Second Half of 2026Benzinga Newsdesk - Jan 8, 2024, 7:17AM
- Deciphera Pharmaceuticals' Preliminary Unaudited Q4 2023 Qinlock Net Product Revenue Of Approximately $46M, Up 40% Y/YBenzinga Newsdesk - Jan 8, 2024, 7:17AM
Monday, November 20, 2023
Tuesday, October 31, 2023
- Stifel Maintains Buy on Deciphera Pharmaceuticals, Raises Price Target to $22Benzinga Newsdesk - Oct 31, 2023, 2:00PM
- HC Wainwright & Co. Maintains Buy on Deciphera Pharmaceuticals, Raises Price Target to $30Benzinga Newsdesk - Oct 31, 2023, 7:36AM
- JonesTrading Upgrades Deciphera Pharmaceuticals to BuyBenzinga Newsdesk - Oct 31, 2023, 5:52AM
Monday, October 30, 2023
- Piper Sandler Upgrades Deciphera Pharmaceuticals to Overweight, Raises Price Target to $23Benzinga Newsdesk - Oct 30, 2023, 12:58PM
- Deciphera Pharmaceuticals' Investigational Drug Shows Encouraging Response Rates In Rare Type Of CancerVandana Singh - Oct 30, 2023, 11:22AM
- Western Digital, JinkoSolar, Lumentum Holdings And Other Big Stocks Moving Higher On MondayLisa Levin - Oct 30, 2023, 10:19AM
- Market-Moving News for October 30thBenzinga Newsdesk - Oct 30, 2023, 8:50AM
- Deciphera Pharma shares are trading higher after the company announced its study of patients with TGCT met its primary and secondary endpoint.Luke J Jacobi - Oct 30, 2023, 8:16AM
- Deciphera Pharmaceuticals Shares Resumed at 7:30:00 AM ET Up 35% Following Primary And Secondary Endpoints Met in TGCT TrialCharles Gross - Oct 30, 2023, 7:34AM
- Deciphera Pharmaceuticals CM Shares To Resume Trade At 7:30 AM ETCharles Gross - Oct 30, 2023, 7:09AM
- Deciphera Pharmaceuticals' Cash, Cash Equivalents, And Marketable Securities Of $376.9M Expected To Provide Cash Runway Into 2026Benzinga Newsdesk - Oct 30, 2023, 7:07AM
- Deciphera Pharmaceuticals Q3 EPS $(0.58) Beats $(0.61) Estimate, Sales $43.31M Beat $39.35M EstimateBenzinga Newsdesk - Oct 30, 2023, 7:05AM
- Deciphera Pharmaceuticals' Motion Phase 3 Study Of Vimseltinib For Tenosynovial Giant Cell Tumor Met Primary Endpoint With Objective Response Rate At Week 25 Of 40% Compared To 0% For PlaceboBenzinga Newsdesk - Oct 30, 2023, 7:03AM
Tuesday, October 10, 2023
Thursday, October 05, 2023
Thursday, September 28, 2023
Tuesday, September 26, 2023
Thursday, August 10, 2023
- Deciphera Pharmaceuticals Sees Renewed Competitive Edge After Theseus Pan-KIT Discontinuation: AnalystVandana Singh - Aug 10, 2023, 2:09PM
- Deciphera Pharmaceuticals shares are trading higher after Stifel upgraded the stock from Hold to Buy.Benzinga Newsdesk - Aug 10, 2023, 12:57PM
- Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2023Benzinga Insights - Aug 10, 2023, 11:00AM
- Global Payments To Rally Around 17%? Here Are 10 Other Analyst Forecasts For ThursdayLisa Levin - Aug 10, 2023, 7:53AM
- HC Wainwright & Co. Reiterates Buy on Deciphera Pharmaceuticals, Maintains $25 Price TargetBenzinga Newsdesk - Aug 10, 2023, 7:49AM
- Stifel Upgrades Deciphera Pharmaceuticals to Buy, Raises Price Target to $20Benzinga Newsdesk - Aug 10, 2023, 5:02AM
Wednesday, August 09, 2023
Tuesday, August 08, 2023
Thursday, May 04, 2023
Wednesday, May 03, 2023
Tuesday, May 02, 2023
Thursday, March 16, 2023
Wednesday, March 15, 2023
- Where Deciphera Pharmaceuticals Stands With AnalystsBenzinga Insights - Mar 15, 2023, 12:01PM
- JMP Securities Reiterates Market Outperform on Deciphera Pharmaceuticals, Maintains $23 Price TargetBenzinga Newsdesk - Mar 15, 2023, 8:07AM
- Reported Late Tuesday March 14, Deciphera Pharmaceuticals Announces QINLOCK Included In NCCN Guidelines For The Treatment Of Second-Line GIST Patients And FDA Grants Breakthrough Therapy Designation For QINLOCK In Second-Line GIST Patients With Mutations In KIT Exon 11 And 17/18Happy Mohamed - Mar 15, 2023, 12:48AM